[{"id":"47b96ada-e4a0-4b3c-9de2-04691e9ba258","acronym":"LAMP-2","url":"https://clinicaltrials.gov/study/NCT06889168","created_at":"2025-06-07T14:47:25.914Z","updated_at":"2025-06-07T14:47:25.914Z","phase":"Phase 1","brief_title":"Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)","source_id_and_acronym":"NCT06889168 - LAMP-2","lead_sponsor":"Columbia University","biomarkers":" VEGFD","pipe":"","alterations":" ","tags":["VEGFD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-05-31"},{"id":"7d1db8e8-7b6d-42c9-9ece-d432ef711cf0","acronym":"MILES","url":"https://clinicaltrials.gov/study/NCT00414648","created_at":"2023-11-02T20:12:03.815Z","updated_at":"2024-07-02T16:35:30.536Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Sirolimus in LAM","source_id_and_acronym":"NCT00414648 - MILES","lead_sponsor":"University of Cincinnati","biomarkers":" VEGFD","pipe":"","alterations":" ","tags":["VEGFD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 12/01/2006","start_date":" 12/01/2006","primary_txt":" Primary completion: 09/01/2010","primary_completion_date":" 09/01/2010","study_txt":" Completion: 02/01/2011","study_completion_date":" 02/01/2011","last_update_posted":"2023-11-02"},{"id":"287a9ac5-c791-438b-9a3b-c10c40baeed2","acronym":"LAM-CAK","url":"https://clinicaltrials.gov/study/NCT05323370","created_at":"2022-04-12T14:53:02.668Z","updated_at":"2024-07-02T16:35:52.027Z","phase":"","brief_title":"Lymphangioleiomyomatosis, a Study on Cathepsin K","source_id_and_acronym":"NCT05323370 - LAM-CAK","lead_sponsor":"University Hospital, Tours","biomarkers":" VEGFD • CTSK","pipe":"","alterations":" ","tags":["VEGFD • CTSK"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 10/30/2022","primary_completion_date":" 10/30/2022","study_txt":" Completion: 10/30/2022","study_completion_date":" 10/30/2022","last_update_posted":"2023-03-29"},{"id":"2060b04c-a3d5-41c3-940a-56df590aaecd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03253913","created_at":"2021-01-18T16:04:28.779Z","updated_at":"2024-07-02T16:35:56.646Z","phase":"Phase 2","brief_title":"Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial","source_id_and_acronym":"NCT03253913","lead_sponsor":"University of Cincinnati","biomarkers":" VEGFD","pipe":"","alterations":" ","tags":["VEGFD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 03/31/2018","start_date":" 03/31/2018","primary_txt":" Primary completion: 10/15/2022","primary_completion_date":" 10/15/2022","study_txt":" Completion: 10/15/2022","study_completion_date":" 10/15/2022","last_update_posted":"2023-02-01"},{"id":"20efeb70-a46d-4b47-9855-0576c986d562","acronym":"","url":"https://clinicaltrials.gov/study/NCT04374747","created_at":"2021-01-18T21:08:05.002Z","updated_at":"2024-07-02T16:36:00.953Z","phase":"","brief_title":"Fruit and Vegetable Intervention in Lactating Women to Reduce Breast Cancer Risk","source_id_and_acronym":"NCT04374747","lead_sponsor":"University of Massachusetts, Amherst","biomarkers":" IL6 • TNFA • CXCL8 • FLT1 • VEGFD • FGF • IL1B • LEP","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • FLT1 • VEGFD • FGF • IL1B • LEP"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/24/2019","start_date":" 10/24/2019","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2022-11-04"},{"id":"6ed25a2c-816b-431f-9aca-3d4920a47247","acronym":"COLA","url":"https://clinicaltrials.gov/study/NCT02484664","created_at":"2021-01-18T11:58:12.435Z","updated_at":"2024-07-02T16:36:18.233Z","phase":"Phase 2","brief_title":"COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC","source_id_and_acronym":"NCT02484664 - COLA","lead_sponsor":"Brigham and Women's Hospital","biomarkers":" VEGFD","pipe":"","alterations":" ","tags":["VEGFD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 06/15/2016","start_date":" 06/15/2016","primary_txt":" Primary completion: 11/19/2018","primary_completion_date":" 11/19/2018","study_txt":" Completion: 11/19/2018","study_completion_date":" 11/19/2018","last_update_posted":"2022-01-20"},{"id":"28eabe08-4713-4401-acdf-9897ef828ff4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04388371","created_at":"2021-01-18T21:11:01.562Z","updated_at":"2024-07-02T16:36:26.628Z","phase":"Phase 1","brief_title":"Glutamine PET Imaging in LAM","source_id_and_acronym":"NCT04388371","lead_sponsor":"Vanderbilt University Medical Center","biomarkers":" VEGFD","pipe":" | ","alterations":" VEGFD elevation","tags":["VEGFD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VEGFD elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 10/18/2019","start_date":" 10/18/2019","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 08/10/2021","study_completion_date":" 08/10/2021","last_update_posted":"2021-08-11"},{"id":"b71768d2-a527-4547-8d52-9b93a4f998ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT01059318","created_at":"2021-01-18T04:10:17.594Z","updated_at":"2024-07-02T16:36:38.424Z","phase":"Phase 2","brief_title":"A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis","source_id_and_acronym":"NCT01059318","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" VEGFD","pipe":"","alterations":" ","tags":["VEGFD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 01/01/2010","start_date":" 01/01/2010","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 06/01/2012","study_completion_date":" 06/01/2012","last_update_posted":"2020-11-19"},{"id":"66bc3f88-573e-483d-a074-c5b181266d2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01297244","created_at":"2021-01-18T05:16:20.218Z","updated_at":"2024-07-02T16:36:39.586Z","phase":"Phase 2","brief_title":"A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT01297244","lead_sponsor":"AVEO Pharmaceuticals, Inc.","biomarkers":" HGF • IL2 • VEGFD • CA9 • VEGFB • VEGFC • CD68","pipe":"","alterations":" ","tags":["HGF • IL2 • VEGFD • CA9 • VEGFB • VEGFC • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 105","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2020-10-27"},{"id":"f76845b1-ea5c-4ee7-9b14-d75b2ede7244","acronym":"","url":"https://clinicaltrials.gov/study/NCT01514123","created_at":"2021-01-18T06:21:50.486Z","updated_at":"2024-07-02T16:36:40.929Z","phase":"Phase 1","brief_title":"Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT01514123","lead_sponsor":"Circadian Technologies Ltd.","biomarkers":" KDR • FLT4 • VEGFD • VEGFC","pipe":"","alterations":" ","tags":["KDR • FLT4 • VEGFD • VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 12/29/2011","start_date":" 12/29/2011","primary_txt":" Primary completion: 02/07/2014","primary_completion_date":" 02/07/2014","study_txt":" Completion: 11/16/2017","study_completion_date":" 11/16/2017","last_update_posted":"2020-09-17"},{"id":"f51bf0ea-18cf-4d7f-8a0b-94c2c6b79ff5","acronym":"LAMP-1","url":"https://clinicaltrials.gov/study/NCT03131999","created_at":"2021-01-18T15:25:53.619Z","updated_at":"2024-07-02T16:36:44.196Z","phase":"Phase 1/2","brief_title":"LAM Pilot Study With Imatinib Mesylate","source_id_and_acronym":"NCT03131999 - LAMP-1","lead_sponsor":"Medical University of South Carolina","biomarkers":" VEGFD","pipe":"","alterations":" ","tags":["VEGFD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 01/23/2018","start_date":" 01/23/2018","primary_txt":" Primary completion: 03/07/2019","primary_completion_date":" 03/07/2019","study_txt":" Completion: 03/07/2019","study_completion_date":" 03/07/2019","last_update_posted":"2020-06-16"}]